{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:02:45Z","timestamp":1790683365684,"version":"4.1.0"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T00:00:00Z","timestamp":1556755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"The European Seven Framework"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>In the absence of consensus, the present meta-analysis was performed to determine an optimal dosing regimen of vancomycin for neonates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A \u2018meta-model\u2019 with 4894 concentrations from 1631 neonates was built using NONMEM, and Monte Carlo simulations were performed to design an optimal intermittent infusion, aiming to reach a target AUC0\u201324 of 400\u2009mg\u00b7h\/L at steady-state in at least 80% of neonates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A two-compartment model best fitted the data. Current weight, postmenstrual age (PMA) and serum creatinine were the significant covariates for CL. After model validation, simulations showed that a loading dose (25\u2009mg\/kg) and a maintenance dose (15\u2009mg\/kg q12h if &lt;35\u2009weeks PMA and 15\u2009mg\/kg q8h if \u226535\u2009weeks PMA) achieved the AUC0\u201324 target earlier than a standard \u2018Blue Book\u2019 dosage regimen in &gt;89% of the treated patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The results of a population meta-analysis of vancomycin data have been used to develop a new dosing regimen for neonatal use and to assist in the design of the model-based, multinational European trial, NeoVanc.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkz158","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T16:14:59Z","timestamp":1553271299000},"page":"2128-2138","source":"Crossref","is-referenced-by-count":54,"title":["Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants"],"prefix":"10.1093","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4285-7067","authenticated-orcid":false,"given":"Evelyne","family":"Jacqz-Aigrain","sequence":"first","affiliation":[{"name":"Department of Pediatric Pharmacology and Pharmacogenetics, H\u00f4pital Robert Debr\u00e9, APHP, Paris, France"},{"name":"Clinical Investigation Center CIC1426, H\u00f4pital Robert Debr\u00e9, Paris, France"},{"name":"University Paris Diderot, Sorbonne Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Leroux","sequence":"additional","affiliation":[{"name":"Department of Pediatric Pharmacology and Pharmacogenetics, H\u00f4pital Robert Debr\u00e9, APHP, Paris, France"},{"name":"Clinical Investigation Center CIC1426, H\u00f4pital Robert Debr\u00e9, Paris, France"},{"name":"Division of Neonatology, Department of Child and Adolescent Medicine, CHU de Rennes, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison H","family":"Thomson","sequence":"additional","affiliation":[{"name":"Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK"},{"name":"Pharmacy Department, Glasgow Royal Infirmary, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Allegaert","sequence":"additional","affiliation":[{"name":"Department of Development and Regeneration, KU Leuven, Leuven, Belgium"},{"name":"Intensive Care, Erasmus MC \u2013 Sophia Children's Hospital, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund V","family":"Capparelli","sequence":"additional","affiliation":[{"name":"Pediatric Pharmacology and Drug Discovery, University of California, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Biran","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit, H\u00f4pital Robert Debr\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, H\u00f4pital de la Timone, APHM, Universit\u00e9 de la M\u00e9diterran\u00e9e, Marseille, France"},{"name":"Service de Pharmacologie Clinique, H\u00f4pital Sainte marguerite, CAP-TV, 13274 Marseille, France"},{"name":"Aix Marseille University, INSERM, IRD, SESSTIM, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Meibohm","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoke-Lin","family":"Lo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia"},{"name":"School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remedios","family":"Marques","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, La Fe Hospital, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Esteban","family":"Peris","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Technology, University of Valencia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irja","family":"Lutsar","sequence":"additional","affiliation":[{"name":"Institute of Medical Microbiology, University of Tartu, Tartu, Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumpei","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Children\u2019s Hospital National Center for Child Health and Development, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidefumi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Development Strategy, Center for Clinical Research and Development, National Center for Child Health and Development, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes N","family":"van den Anker","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Glasgow Royal Infirmary, Glasgow, UK"},{"name":"Division of Clinical Pharmacology, Children's National Medical Center, Washington, DC, USA"},{"name":"Departments of Pediatrics, Pharmacology & Physiology, George Washington University, School of Medicine and Health Sciences, Washington, DC, USA"},{"name":"Department of Paediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Sharland","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Disease Unit, St George\u2019s Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1830-338X","authenticated-orcid":false,"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pediatric Pharmacology and Pharmacogenetics, H\u00f4pital Robert Debr\u00e9, APHP, Paris, France"},{"name":"Department of Pharmacy, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, China"},{"name":"Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,5,2]]},"reference":[{"key":"2019071909300918200_dkz158-B1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2165\/00003088-200443070-00001","article-title":"Vancomycin: pharmacokinetics and administration regimens in neonates","volume":"43","author":"de Hoog","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"2019071909300918200_dkz158-B2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.siny.2012.10.003","article-title":"Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration","volume":"18","author":"Jacqz-Aigrain","year":"2013","journal-title":"Semin Fetal Neonatal Med"},{"key":"2019071909300918200_dkz158-B3","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/archdischild-2014-306873","article-title":"Therapeutic guidelines for prescribing antibiotics in neonates should be evidence-based: a French national survey","volume":"100","author":"Leroux","year":"2015","journal-title":"Arch Dis Child"},{"key":"2019071909300918200_dkz158-B4","doi-asserted-by":"crossref","first-page":"e012675.","DOI":"10.1136\/bmjopen-2016-012675","article-title":"Using a simple point-prevalence survey to define appropriate antibiotic prescribing in hospitalised children across the UK","volume":"3","author":"Gharbi","year":"2016","journal-title":"BMJ Open"},{"key":"2019071909300918200_dkz158-B5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12887-015-0359-y","article-title":"High variability in the dosing of commonly used antibiotics revealed by a Europe-wide point prevalence study: implications for research and dissemination","volume":"15","author":"Metsvaht","year":"2015","journal-title":"BMC Pediatr"},{"key":"2019071909300918200_dkz158-B6","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1093\/jac\/dkr351","article-title":"Variation in gentamicin and vancomycin dosage and monitoring in UK neonatal units","volume":"66","author":"Kadambari","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2019071909300918200_dkz158-B7","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1097\/INF.0000000000000719","article-title":"Australia-wide point prevalence survey of antimicrobial prescribing in neonatal units: how much and how good?","volume":"34","author":"Osowicki","year":"2015","journal-title":"Pediatr Inf Dis J"},{"key":"2019071909300918200_dkz158-B8","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1586\/17512433.2015.1060124","article-title":"How to use vancomycin optimally in neonates: remaining questions","volume":"8","author":"Jacqz-Aigrain","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2019071909300918200_dkz158-B9","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1007\/s11095-014-1361-z","article-title":"Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration","volume":"31","author":"De Cock","year":"2014","journal-title":"Pharm Res"},{"key":"2019071909300918200_dkz158-B10","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1128\/AAC.02214-15","article-title":"Clinical utility and safety of a model-based patient-tailored dose of vancomycin in neonates","volume":"60","author":"Leroux","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071909300918200_dkz158-B11"},{"key":"2019071909300918200_dkz158-B12","first-page":"154","article-title":"Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R","author":"Comets","year":"2008"},{"key":"2019071909300918200_dkz158-B13","doi-asserted-by":"crossref","DOI":"10.1093\/med\/9780199573585.001.0001","volume-title":"Manual of Childhood Infections. The Blue Book","author":"Sharland","year":"2011"},{"key":"2019071909300918200_dkz158-B14","doi-asserted-by":"crossref","first-page":"F221","DOI":"10.1136\/fn.81.3.F221","article-title":"Pharmacokinetics and dose requirements of vancomycin in neonates","volume":"81","author":"Grimsley","year":"1999","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"2019071909300918200_dkz158-B15","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1177\/00912700122010898","article-title":"The influences of renal function and maturation on vancomycin elimination in newborns and infants","volume":"41","author":"Capparelli","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"2019071909300918200_dkz158-B16","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1185\/146300903322012040","article-title":"Prospective evaluation of neonatal vancomycin dosage guidelines and population parameter estimates","volume":"5","author":"Thomson","year":"2003","journal-title":"Paediatr Perinat Drug Ther"},{"key":"2019071909300918200_dkz158-B17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2125.2006.02725.x","article-title":"Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance","volume":"63","author":"Anderson","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"2019071909300918200_dkz158-B18","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1128\/AAC.01370-09","article-title":"Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination","volume":"54","author":"Lo","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071909300918200_dkz158-B19","doi-asserted-by":"crossref","first-page":"F365","DOI":"10.1136\/adc.2010.196402","article-title":"Vancomycin prescription in neonates and young infants: toward a simplified dosage","volume":"96","author":"Oudin","year":"2011","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"2019071909300918200_dkz158-B20","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1177\/2160763X12456843","article-title":"Vancomycin: predictive performance of a population pharmacokinetic model and optimal dose in neonates and young infants","volume":"1","author":"Marsot","year":"2012","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2019071909300918200_dkz158-B21","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/j.1875-9114.2012.01029.x","article-title":"Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations","volume":"32","author":"Mehrotra","year":"2012","journal-title":"Pharmacotherapy"},{"key":"2019071909300918200_dkz158-B22","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1136\/archdischild-2012-303197","article-title":"Continuous infusion of vancomycin in neonates","volume":"98","author":"Patel","year":"2013","journal-title":"Arch Dis Child"},{"key":"2019071909300918200_dkz158-B23","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/j.1365-2125.2012.04406.x","article-title":"External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings","volume":"75","author":"Zhao","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"2019071909300918200_dkz158-B24","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1136\/archdischild-2012-302765","article-title":"Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring","volume":"98","author":"Zhao","year":"2013","journal-title":"Arch Dis Child"},{"key":"2019071909300918200_dkz158-B25","doi-asserted-by":"crossref","first-page":"1974972","DOI":"10.1155\/2016\/1974972","article-title":"Different vancomycin immunoassays contribute to the variability in vancomycin trough measurements in neonates","volume":"2016","author":"Samardzic","year":"2016","journal-title":"Biomed Res Int"},{"key":"2019071909300918200_dkz158-B26","doi-asserted-by":"crossref","first-page":"206.","DOI":"10.1186\/s12887-016-0753-0","article-title":"Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?","volume":"16","author":"Padari","year":"2016","journal-title":"BMC Pediatr"},{"key":"2019071909300918200_dkz158-B27","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology\u2014drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N Engl J Med"},{"key":"2019071909300918200_dkz158-B28"},{"key":"2019071909300918200_dkz158-B29"},{"key":"2019071909300918200_dkz158-B30","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2165\/00003088-200847040-00002","article-title":"Facilitation of drug evaluation in children by population methods and modelling","volume":"47","author":"Tod","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"2019071909300918200_dkz158-B31","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/jphp.12637","article-title":"How to optimise drug study design: pharmacokinetics and pharmacodynamics studies introduced to paediatricians","volume":"69","author":"Vermeulen","year":"2017","journal-title":"J Pharm Pharmacol"},{"key":"2019071909300918200_dkz158-B32","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s40262-015-0291-1","article-title":"Pharmacokinetic studies in neonates: the utility of an opportunistic sampling design","volume":"54","author":"Leroux","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"2019071909300918200_dkz158-B33","doi-asserted-by":"crossref","first-page":"416.","DOI":"10.1097\/FTD.0b013e3182866a99","article-title":"The importance of knowing how vancomycin is measured when interpreting its pharmacokinetic results","volume":"35","author":"Zhao","year":"2013","journal-title":"Ther Drug Monit"},{"key":"2019071909300918200_dkz158-B34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cca.2014.12.012","article-title":"Novel LC-MS\/MS method for plasma vancomycin: comparison with immunoassays and clinical impact","volume":"441","author":"Oyaert","year":"2015","journal-title":"Clin Chim Acta"},{"key":"2019071909300918200_dkz158-B35","doi-asserted-by":"crossref","first-page":"e01249","DOI":"10.1128\/AAC.01249-17","article-title":"Influence of mechanical ventilation on the pharmacokinetics of vancomycin administered by continuous infusion in critically ill patients","volume":"61","author":"Medell\u00edn-Garibay","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071909300918200_dkz158-B36","doi-asserted-by":"crossref","first-page":"F236","DOI":"10.1136\/archdischild-2015-308459","article-title":"A propensity-matched cohort study of vancomycin-associated nephrotoxicity in neonates","volume":"101","author":"Constance","year":"2016","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"2019071909300918200_dkz158-B37","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1186\/s13054-014-0632-8","article-title":"Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy: a matched cohort study","volume":"18","author":"Donatello","year":"2014","journal-title":"Crit Care"},{"key":"2019071909300918200_dkz158-B38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2431-12-45","article-title":"Pharmacokinetics and pharmacodynamics of medication in asphyxiated newborns during controlled hypothermia. The PharmaCool multicenter study","volume":"12","author":"de Haan","year":"2012","journal-title":"BMC Paediatr"},{"key":"2019071909300918200_dkz158-B39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ddtec.2016.08.004","article-title":"Translational PK\/PD of anti-infective therapeutics","volume":"21-22","author":"Rathi","year":"2016","journal-title":"Drug Discov Today Technol"},{"key":"2019071909300918200_dkz158-B40","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/archdischild-2013-303721","article-title":"Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling","volume":"99","author":"Admiraal","year":"2014","journal-title":"Arch Dis Child"},{"key":"2019071909300918200_dkz158-B41","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1365-2125.2012.04205.x","article-title":"Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics","volume":"74","author":"Svensson","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"2019071909300918200_dkz158-B42","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of Infectious Diseases Pharmacists","volume":"66","author":"Ruback","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"2019071909300918200_dkz158-B43","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","article-title":"Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"42","author":"Sakoulas","year":"2004","journal-title":"J Clin Microbiol"},{"key":"2019071909300918200_dkz158-B44","doi-asserted-by":"crossref","first-page":"E37","DOI":"10.1111\/j.1469-0691.2011.03752.x","article-title":"The role of pharmacokinetics\/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach","volume":"18","author":"Mouton","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2019071909300918200_dkz158-B45","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"van Hal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071909300918200_dkz158-B46","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/596757","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2019071909300918200_dkz158-B47","doi-asserted-by":"crossref","first-page":"e00280","DOI":"10.1128\/AAC.00280-17","article-title":"Pharmacokinetic assessment of vancomycin loading dose in critically ill patients","volume":"61","author":"\u00c1lvarez","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071909300918200_dkz158-B48","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1093\/jpids\/piu110","article-title":"Pharmacodynamic characteristics of nephrotoxicity associated with vancomycin use in children","volume":"4","author":"Le","year":"2015","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2019071909300918200_dkz158-B49","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/cpt.726","article-title":"The nephrotoxicity of vancomycin","volume":"102","author":"Filippone","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2019071909300918200_dkz158-B50","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/QCO.0000000000000263","article-title":"Vancomycin toxicity in neonates: a review of the evidence","volume":"29","author":"Lestner","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"2019071909300918200_dkz158-B51","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000343162","article-title":"Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic\u2013pharmacodynamic analysis in patients with methicillin-resistant Staphylococcus aureus pneumonia","volume":"58","author":"Suzuki","year":"2012","journal-title":"Chemotherapy"},{"key":"2019071909300918200_dkz158-B52","doi-asserted-by":"crossref","first-page":"e01684","DOI":"10.1128\/AAC.01684-17","article-title":"Identification of vancomycin exposure\u2013toxicity thresholds in hospitalized patients receiving intravenous vancomycin","volume":"62","author":"Zasowski","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071909300918200_dkz158-B53","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration\u2013time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2019071909300918200_dkz158-B54","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/cid\/civ498","article-title":"Recent updates on the role of pharmacokinetics\u2013pharmacodynamics in antimicrobial susceptibility testing as applied to clinical practice","volume":"61","author":"Labreche","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2019071909300918200_dkz158-B55","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s12519-014-0493-x","article-title":"Dosage individualization in children: integration of pharmacometrics in clinical practice","volume":"10","author":"Zhao","year":"2014","journal-title":"World J Pediatr"},{"key":"2019071909300918200_dkz158-B56","first-page":"e01293","article-title":"A quasi-experiment to study the impact of vancomycin area under the concentration\u2013time curve-guided dosing on vancomycin-associated nephrotoxicity","volume":"22","author":"Finch","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071909300918200_dkz158-B57","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1128\/AAC.01653-13","article-title":"Are vancomycin trough concentrations adequate for optimal dosing?","volume":"58","author":"Neely","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2019071909300918200_dkz158-B58","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/0897190016642692","article-title":"Are vancomycin trough concentrations of 15 to 20 mg\/L associated with increased attainment of an AUC\/MIC \u2265400 in patients with presumed MRSA infection?","volume":"30","author":"Hale","year":"2017","journal-title":"J Pharm Pract"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/advance-article-pdf\/doi\/10.1093\/jac\/dkz158\/28553921\/dkz158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/8\/2128\/28963255\/dkz158.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T09:30:53Z","timestamp":1563528653000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/8\/2128\/5485014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,2]]},"references-count":58,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,5,2]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz158","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2019,5,2]]}}}